Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct epidemiological patterns of allergic disease comorbidity across elementary school grades in Taiwan.

Pediatric research·2026
Same author

Response to "Comment on 'The characteristics and risk factors of cerebrovascular events in young systemic lupus erythematosus patients: A case-control study".

Journal of the Formosan Medical Association = Taiwan yi zhi·2026
Same author

H₂O₂-induced green synthesis of EGCG-flavonoid carrier-free nanoparticles:The role of hydroxyl group number governing formation and function.

Food chemistry·2026
Same author

Novel CD8<sup>+</sup> Regulatory T Cells Attenuate Eosinophilic Infiltration in a Murine Allergic Asthma Model.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Liver-directed AAV-IL-10 therapy enhances CD8<sup>+</sup> T cell-mediated immunity against hepatocellular carcinoma.

Journal for immunotherapy of cancer·2026
Same author

Polysaccharide-based inflammatory microenvironment-responsive nanocarriers for ulcerative colitis: Advances in design, mechanisms, and therapeutic applications.

Carbohydrate polymers·2026

Related Experiment Video

Updated: Jun 22, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Gene therapy for allergic diseases.

Ya-Hui Chuang1, Yao-Hsu Yang, Si-Jie Wu

  • 1Department of Clinical Laboratory Sciences and Medical Biothechnology, National Taiwan University, Taipei, Taiwan.

Current Gene Therapy
|June 13, 2009
PubMed
Summary

Gene therapy offers a promising approach to treat allergic diseases by modulating immune responses. This method involves delivering therapeutic DNA to correct immune imbalances, providing a potentially convenient and effective alternative to traditional treatments.

More Related Videos

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay
06:08

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay

Published on: September 22, 2023

Related Experiment Videos

Last Updated: Jun 22, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay
06:08

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay

Published on: September 22, 2023

Area of Science:

  • Immunology
  • Allergology
  • Gene Therapy

Background:

  • Allergic diseases are linked to T helper 2 (TH2) immune responses, characterized by eosinophilic inflammation and impaired regulatory T cell function.
  • Key TH2 cytokines (IL-4, IL-5, IL-13) drive IgE production, mast cell differentiation, and eosinophil activation, contributing to allergic pathology.
  • Current treatments like antihistamines and corticosteroids are effective but require long-term administration and can be costly.

Purpose of the Study:

  • To review recent advancements in gene therapy for allergic diseases.
  • To discuss the potential of gene therapy as a convenient and effective treatment modality.
  • To highlight challenges associated with the clinical application of gene therapy in allergy.

Main Methods:

  • Review of current literature on gene therapy applications in allergic diseases.
  • Analysis of in vivo DNA delivery methods for therapeutic protein or allergen administration.
  • Discussion of immune response modulation strategies via gene therapy.

Main Results:

  • Gene therapy can effectively modulate allergic immune responses by delivering therapeutic DNA.
  • Plasmid DNA delivery in vivo offers a convenient and potentially long-lasting treatment approach.
  • Gene therapy presents an alternative to conventional treatments, addressing limitations of cost and administration.

Conclusions:

  • Gene therapy shows significant potential for treating allergic diseases, including allergic asthma and atopic dermatitis.
  • In vivo gene therapy offers a promising avenue for immune response modulation in allergy.
  • Further research is needed to overcome challenges and facilitate the clinical translation of gene therapy for allergic conditions.